文献速递复苏、休克与脓毒症重症综合管理与镇静镇痛

异基因造血干细胞移植后脓毒性休克:多中心ICU队列的结局与预后因素

Septic Shock After Allogeneic Hematopoietic Stem Cell Transplantation: Outcomes and Prognostic Factors in a Multicenter ICU Cohort.
PubMed 文献 · Chest · 2026-08-29
一句话结论allo-HSCT后脓毒性休克90天死亡率高达63%,真菌病原学阳性、SOFA评分和中性粒细胞减少与90天生存独立相关;早期氨基糖苷类使用与更高生存相关但关联随时间变化,不支持直接因果解释。

本多中心回顾性队列纳入2015-2020年ICU收治的1,164例allo-HSCT受者,其中38%(444例)因脓毒性休克入ICU。中位SOFA评分8分,62%获得微生物学证据(真菌17%),呼吸道为最常见感染源(43%)。90天和3年死亡率分别为63%和81%。扩展Cox模型显示真菌病原学阳性(HR 1.78)、SOFA评分(HR 1.07)和中性粒细胞减少(HR 3.94)与90天生存独立相关;48小时landmark分析中早期氨基糖苷类使用与更高90天生存相关(HR 0.46),但时间变化分析提示关联不恒定。

要点

  • allo-HSCT后因脓毒性休克入ICU者90天死亡率63%、3年死亡率81%,应早期识别并积极复苏。
  • 年龄≥56岁(HR 1.36,95%CI 0.99-1.87)、GVHD类型和早期细菌病原学阳性(HR 0.90,95%CI 0.64-1.26)与90天生存无独立关联。
  • 62%获得微生物学证据,呼吸道为最常见感染源(43%),真菌占17%,提示需重视呼吸道感染和真菌覆盖。

适用人群与场景

  • 2015-2020年多中心ICU收治的异基因造血干细胞移植(allo-HSCT)受者,因脓毒性休克入ICU者(n=444)。
  • 排除人群及其他纳入细节原文未提及。

诊断标准与关键阈值

  • 脓毒性休克诊断标准原文未提及具体定义。
  • 中位SOFA评分8分(IQR 6-11),作为病情严重度评估指标。
  • 中性粒细胞减少与90天生存独立相关(HR 3.94),但具体定义原文未提及。

处置流程与药物剂量

  • 原文未提及具体的复苏流程或药物剂量方案。
  • 早期氨基糖苷类使用(48小时内)在landmark分析中与更高90天生存相关(HR 0.46,95%CI 0.33-0.64),但时间变化分析提示关联不恒定,不构成因果推荐;具体药物、剂量、途径和疗程原文未提及。

红旗征与不能漏的情况

  • 需要侵入性机械通气(64%)或肾脏替代治疗(32%)提示病情危重。

研究设计与关键结果

  • 多中心回顾性队列研究,纳入1,164例ICU收治的allo-HSCT受者,其中444例(38%)因脓毒性休克入ICU。
  • 中位SOFA评分8(IQR 6-11);62%(261例)获得微生物学证据,真菌占17%(74例);呼吸道为最常见感染源(43%,180例)。
  • 64%(284例)需要侵入性机械通气,32%(143例)需要肾脏替代治疗。
  • 90天死亡率为63%(280例),3年死亡率为81%(350例)。
  • 年龄≥56岁(HR 1.36,95%CI 0.99-1.87)、GVHD类型和早期细菌病原学阳性(HR 0.90,95%CI 0.64-1.26)与90天生存无独立关联。

证据类型、等级与局限

  • 证据类型:多中心回顾性队列研究。
  • 局限:回顾性设计、观察性研究,氨基糖苷类与结局的关联可能存在指征混杂,时间变化分析提示关联不恒定,不支持因果推断,需前瞻性验证。

对床旁实践的改变

  • 对allo-HSCT后脓毒性休克患者,应认识到90天死亡率高达63%,需早期积极评估和治疗。
  • 真菌病原学阳性和中性粒细胞减少提示预后更差,应重视真菌筛查和中性粒细胞减少的管理。
  • 早期氨基糖苷类使用与更好生存的关联不支持常规推荐使用,需个体化评估并等待前瞻性研究。
  • 呼吸道为最常见感染源,应关注呼吸道感染的诊断和治疗。

指南或共识出处

  • 原文未提及

以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。

英文原文(摘要)· 点击展开

BACKGROUND: Septic shock is a major cause of ICU admission among recipients of allogeneic hematopoietic stem cell transplantation (allo-HSCT), yet data on its epidemiologic features and prognosis remain limited.

RESEARCH QUESTION: What are the outcomes, independent prognostic factors, and associations of allo-HSCT that may inform early management?

STUDY DESIGN AND METHODS: We performed a multicenter retrospective cohort study including recipients of allo-HSCT admitted to the ICU with septic shock between 2015 and 2020.

RESULTS: Among 1,164 recipients of allo-HSCT hospitalized in ICU, 38% (n = 444) were admitted for septic shock. The median Sequential Organ Failure Assessment (SOFA) score was 8 (interquartile range, 6-11). Microbiological documentation was obtained in 62% (n = 261), including fungal pathogens in 17% (n = 74). The respiratory tract was the most common infection source (43%; n = 180). Invasive mechanical ventilation and renal replacement therapy were required in 64% (n = 284) and 32% (n = 143), respectively. Mortality at 90 days and 3 years was 63% (n = 280) and 81% (n = 350), respectively. In the extended Cox model, fungal documentation (hazard ratio [HR], 1.78 [95% CI, 1.19-2.67]; P = .005), SOFA score (HR, 1.07 [95% CI, 1.02-1.13]; P = .007), and neutropenia (HR, 3.94 [95% CI, 1.18-13.1]; P = .026) were associated independently with 90-day survival. In a 48-hour landmark analysis, early aminoglycoside use was associated with higher 90-day survival (HR, 0.46 [95% CI, 0.33-0.64]; P < .001). However, time-varying analyses indicated a nonconstant association over time. Age of ≥ 56 years (HR, 1.36 [95% CI, 0.99-1.87]), graft-versus-host disease type, and early bacterial documentation (HR, 0.90 [95% CI, 0.64-1.26]) were not associated with 90-day survival.

INTERPRETATION: Our results show that septic shock after allo-HSCT carries a high mortality (63% at 90 days), largely driven by host-related factors and initial illness severity. The association between aminoglycoside use and outcome is complex, does not support a straightforward causal interpretation, and warrants further prospective evaluation.

来源:Chest,查看原文。版权归原作者所有。

参考来源

  1. Subileau M, Chean D, Dupont T, et al. Septic Shock After Allogeneic Hematopoietic Stem Cell Transplantation: Outcomes and Prognostic Factors in a Multicenter ICU Cohort. Chest. 2026. PMID: 42665126. doi:10.1016/j.chest.2026.06.075

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。